Development and Structural Analysis of Antibody Therapeutics for Filoviruses

The filoviruses, including ebolaviruses and marburgviruses, are among the world's deadliest pathogens. As the only surface-exposed protein on mature virions, their glycoprotein GP is the focus of current therapeutic monoclonal antibody discovery efforts. With recent technological developments, potent antibodies have been identified from immunized animals and human survivors of virus infections and have been characterized functionally and structurally. Structural insight into how the most successful antibodies target GP further guides vaccine development. Here we review the recent developments in the identification and characterization of neutralizing antibodies and cocktail immunotherapies.

Automated summary

This article reviews the recent developments in the research of filoviruses, particularly ebolaviruses and marburgviruses. It focuses on the discovery and functional characterization of therapeutic monoclonal antibodies targeting the glycoprotein GP of these viruses, as well as the structural insights guiding vaccine development.